STOCK TITAN

Yarrow Bioscience holders report 1.16% beneficial stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. (YARW) is the issuer covered by an ownership amendment from AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik. It states that the four reporting persons ceased to be beneficial owners of more than 5% of the common stock on November 13, 2026.

The reporting persons each reported 178,179 shares (1.16%) as beneficially owned. That amount includes 22,331 common shares held directly by AI Biotechnology and pre-funded warrants exercisable for 155,848 shares. The three other reporting persons may be deemed to beneficially own these securities through the stated control relationships, but each disclaims beneficial ownership.

Beneficially owned shares 178,179 shares Amount reported by each reporting person; includes shares issuable upon exercise of pre-funded warrants.
Reported ownership percentage 1.16% Percentage of the common stock, calculated using a denominator that includes warrant shares.
Common shares held directly 22,331 shares Held directly by AI Biotechnology LLC.
Shares issuable under warrants 155,848 shares Issuable upon exercise of pre-funded warrants held directly by AI Biotechnology LLC.
Common shares outstanding 15,234,944 shares Issued and outstanding as of November 3, 2026.
beneficial ownership regulatory
"Aggregate amount beneficially owned by each reporting person"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared Voting Power 178,179.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
pre-funded warrants financial
"shares of Common Stock issuable upon the exercise of pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
disclaims beneficial ownership regulatory
"each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many YARW shares did the reporting persons report as beneficially owned?

The reporting persons reported 178,179 shares (1.16%) as beneficially owned, including 22,331 common shares held directly by AI Biotechnology LLC and 155,848 shares issuable upon exercise of its pre-funded warrants.

When did the YARW reporting persons cease to own more than 5%?

They stated that they ceased to be beneficial owners of more than 5% of the outstanding common stock on November 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





92941V407

(CUSIP Number)
Alejandro Moreno
c/o Access Industries, Inc., 40 West 57th Street, 28th Floor
New York, NY, 10019
(212) 247-6400


Langhorne S. Perrow
c/o Access Industries, Inc., 40 West 57th Street, 28th Floor
New York, NY, 10019
(212) 247-6400


Nicholas P. Pellicani
Debevoise & Plimpton LLP, The Northcliffe, 28 Tudor St.
London, X0, EC4Y 0AY
44 20 7786 9000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
11/13/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
Rows 8, 10 and 11: The total number of shares of common stock, par value $0.0001 per share ("Common Stock"), of Yarrow Bioscience, Inc. (the "Issuer") reported as beneficially owned includes (i) 22,331 shares of Common Stock held directly by AI Biotechnology LLC ("AI Biotechnology") and (ii) 155,848 shares of Common Stock issuable upon the exercise of pre-funded warrants ("Warrants") held directly by AI Biotechnology. Row 13: The percent of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 8, 10 and 11 above and, as the denominator, the sum of (i) 15,234,944 shares of Common Stock issued and outstanding as of November 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 13, 2026, and (ii) 155,848 shares of Common Stock issuable upon the exercise of Warrants held by AI Biotechnology.


SCHEDULE 13D




Comment for Type of Reporting Person:
Rows 8, 10 and 11: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 22,331 shares of Common Stock held directly by AI Biotechnology and (ii) 155,848 shares of Common Stock issuable upon the exercise of Warrants held directly by AI Biotechnology. Row 13: The percent of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 8, 10 and 11 above and, as the denominator, the sum of (i) 15,234,944 shares of Common Stock issued and outstanding as of November 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 13, 2026, and (ii) 155,848 shares of Common Stock issuable upon the exercise of Warrants held by AI Biotechnology.


SCHEDULE 13D




Comment for Type of Reporting Person:
Rows 8, 10 and 11: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 22,331 shares of Common Stock held directly by AI Biotechnology and (ii) 155,848 shares of Common Stock issuable upon the exercise of Warrants held directly by AI Biotechnology. Row 13: The percent of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 8, 10 and 11 above and, as the denominator, the sum of (i) 15,234,944 shares of Common Stock issued and outstanding as of November 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 13, 2026, and (ii) 155,848 shares of Common Stock issuable upon the exercise of Warrants held by AI Biotechnology.


SCHEDULE 13D




Comment for Type of Reporting Person:
Rows 8, 10 and 11: The total number of shares of Common Stock of the Issuer reported as beneficially owned includes (i) 22,331 shares of Common Stock held directly by AI Biotechnology and (ii) 155,848 shares of Common Stock issuable upon the exercise of Warrants held directly by AI Biotechnology. Row 13: The percent of Common Stock reported as beneficially owned is calculated based on the number of shares of Common Stock described in Rows 8, 10 and 11 above and, as the denominator, the sum of (i) 15,234,944 shares of Common Stock issued and outstanding as of November 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 13, 2026, and (ii) 155,848 shares of Common Stock issuable upon the exercise of Warrants held by AI Biotechnology.


SCHEDULE 13D


AI Biotechnology LLC
Signature:/s/ Alejandro Moreno
Name/Title:By: Access Industries Management, LLC, its Manager; its Executive Vice President/Alejandro Moreno
Date:11/20/2026
Access Industries Holdings LLC
Signature:/s/ Alejandro Moreno
Name/Title:By: Access Industries Management, LLC, its Manager; its Executive Vice President/Alejandro Moreno
Date:11/20/2026
Access Industries Management, LLC
Signature:/s/ Alejandro Moreno
Name/Title:By: Executive Vice President/Alejandro Moreno
Date:11/20/2026
Len Blavatnik
Signature:*
Name/Title:Len Blavatnik
Date:11/20/2026
Comments accompanying signature:
* The undersigned, by signing his name hereto, executes this Amendment No. 2 to Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith. By: /s/ Alejandro Moreno Name: Alejandro Moreno Attorney-in-Fact

Keep reading